Atezolizumab for the treatment of renal cell carcinoma

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012: globocan 2012. Int J Cancer. 2015 1;136(5):E359–86.
   PubMed Web of Science ®Google Scholar
• Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75(1):74–84.
   PubMed Web of Science ®Google Scholar
• Fisher R, Gore M, Larkin J. Current and future systemic treatments for renal cell carcinoma. Semin Cancer Biol. 2013;23(1):38–45.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530.
   PubMed Web of Science ®Google Scholar
• Heng DYC, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–5799.
   PubMed Web of Science ®Google Scholar
• Alsharedi M, Katz H. Check point inhibitors a new era in renal cell carcinoma treatment. Med Oncol. 2018;35(6):85.
   PubMed Web of Science ®Google Scholar
• Escudier B, Cosaert J, Jethwa S. Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. Biologics. 2008;2(3):517–530.
   PubMedGoogle Scholar
• Powles T, Staehler M, Ljungberg B, et al. European association of urology guidelines for clear cell renal cancers that are resistant to vascular endothelial growth factor receptor–targeted therapy. Eur Urol. 2016;70(5):705–706.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015 5;373(19):1803–1813.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018 5;378(14):1277–1290.
   PubMed Web of Science ®Google Scholar
• Powles T, Albiges L, Staehler M, et al. Updated European association of urology guidelines: recommendations for the treatment of first-line metastatic clear cell renal cancer. Eur Urol. 2018;73(3):311–315.
   PubMed Web of Science ®Google Scholar
• Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404–2415.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019 21;380(12):1103–1115.
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019 21;380(12):1116–1127.
   PubMed Web of Science ®Google Scholar
• Research C for DE and FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma. FDA [Internet]. 2019 Apr 22 [cited 2019 Oct 28]. Available from: http://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-plus-axitinib-advanced-renal-cell-carcinoma
   Google Scholar
• chmp-post-authorisation-summary-positive-opinion-keytruda-ii-69_en.pdf [Internet]. [cited 2019 Oct 28]. Available from: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-keytruda-ii-69_en.pdf
   Google Scholar
• Albiges L, Powles T, Staehler M, et al. Updated European association of urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma. Eur Urol. 2019;76(2):151–156.
   PubMed Web of Science ®Google Scholar
• Research C for DE and. FDA approves avelumab plus axitinib for renal cell carcinoma. FDA [Internet]. 2019 May 15 [cited 2019 Oct 28]. Available from: http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avelumab-plus-axitinib-renal-cell-carcinoma
   Google Scholar
• McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749–757.
   PubMed Web of Science ®Google Scholar
• Stroh M, Winter H, Marchand M, et al. Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma. ClinPharmacolTher. 2017;102(2):305–312.
   Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567.
   PubMed Web of Science ®Google Scholar
• Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(6):1757–1761.
   PubMed Web of Science ®Google Scholar
• Elamin YY, Rafee S, Toomey S, et al. Immune effects of bevacizumab: killing two birds with one stone. Cancer Microenviron. 2015;8(1):15–21.
   PubMed Web of Science ®Google Scholar
• Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558–562.
   PubMed Web of Science ®Google Scholar
• Mizugaki H, Yamamoto N, Murakami H, et al. Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. Invest New Drugs. 2016;34(5):596–603.
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–1920.
   PubMed Web of Science ®Google Scholar
• Tecentriq-epar-product-information_en.pdf [Internet]. [cited 2019 Oct 16]. Available from: https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf
   Google Scholar
• McDermott DF, Sosman JA, Sznol M, et al. Atezolizumab, an anti–programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol. 2016;34(8):833–842.
   PubMed Web of Science ®Google Scholar
• Wallin JJ, Bendell JC, Funke R, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7(1):12624.
   PubMedGoogle Scholar
• Rini BH, Atkins M, McDermott D, et al. Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC). ESMO Abstract LBA31; 2018.
   Google Scholar
• Pichler M, Hutterer GC, Chromecki TF, et al. External validation of the leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology. J Urol. 2011;186(5):1773–1778.
   PubMed Web of Science ®Google Scholar
• A study of atezolizumab as adjuvant therapy in participants with renal cell carcinoma (RCC) at high risk of developing metastasis following nephrectomy - full text view - clinicaltrials.gov [Internet]. [cited 2019 Oct 16]. Available from: https://clinicaltrials.gov/ct2/show/NCT03024996
   Google Scholar
• Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748–757.
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentrerandomised controlled trial. Lancet. 2017;389(10066):255–265.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121.
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229.
   PubMed Web of Science ®Google Scholar
• Lenvatinib/Everolimus or Lenvatinib/PembrolizumabVersusSunitinib alone as treatment of advanced renal cell carcinoma - full text view - clinicaltrials.gov [Internet]. [cited 2019 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02811861
   Google Scholar
• A study of nivolumab combined with cabozantinib compared to sunitinib in previously untreated advanced or metastatic renal cell carcinoma - full text view - clinicaltrials.gov [Internet]. [cited 2019 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03141177
   Google Scholar
• A biomarker driven trial with nivolumab and ipilimumab or vegfr tki in naïve metastatic kidney cancer - full text view - clinicaltrials.gov [Internet]. [cited 2019 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02960906
   Google Scholar